Medical network - on September 18, the update need some pharmaceutical giant powerful impetus, these giants like streams in the stones, helps to clearly outline the trajectory of the pharmaceutical industry. The tide of the past decade has changed these giants, but some of these giants have moved far ahead of others, with a story behind them.
Back in 2007, some of the biggest pharma companies were still the industry's biggest. Among them, Johnson & Johnson (Johnson & Johnson) revenues from $61 billion to more than $72 billion now, Pfizer (Pfizer) from the time of the $48 billion to more than $53 billion now, Roche (Roche) increased from $38 billion to $50 billion now, Novartis (Novartis) increased from $38 billion to $49 billion today.
FIG. 1 revenue comparison of pharmaceutical giants: 2007 vs. 2016
Gilead "born in the sky"
Several of the Top 15 pharmaceutical companies that rank in 2016 are not even close to the entry level of Top 15 in 2007. For example, thanks to Sovaldi and Harvoni, the "blockbuster" class of hepatitis c drugs, Gilead Sciences has leapt to the top echelons of the pharmaceutical industry. But in 2007, gilead was a major anti-hiv drug producer, and its revenues hit a new high of $4.2 billion. Last year, the figure was nearly $31 billion, about seven times that of 2007.
In early 2008, after gilead reported results, the Los Angeles times noted that the field of HIV treatment would eventually be profitable. In stark contrast, other drug companies are shunning the treatment. At that time, John Martin, chief executive of gilead (John Martin) told the Los Angeles times, many pharmaceutical companies are intimidated, mainly because of HIV drugs facing unprecedented political and economic pressure.
Since then, gilead has been under fire for pricing its HIV drugs (and pricing of HCV drugs). Over time, however, gilead's drugs have been treated with millions of patients, and its income from HIV treatment has increased to nearly $13 billion. Now, in terms of revenue growth, gilead as other industry upstart, facing the pressure of the implementation of mergers and acquisitions, such ability is expected to return its operating revenue growth track.
BMS is uneventful
Bristol-myers Squibb's development over the years is another completely different picture. The company's operating income in 2016 was almost the same as it was in 2007, at $19 billion. But under these figures, the changes that take place are multifaceted.
BMS is consciously has started to shrink its size: in 2009, in a $7.3 billion deal, the stripping the Mead Johnson nutritionals business (Mead Johnson), it is one of the asset sales action of BMS, purpose is to promote the "pearls" of smaller deals. At the time, BMS had big ambitions in the field of diabetes treatment, and drugs such as Onglyza and Farxiga were under development. BMS has teamed up with AstraZeneca in this field and bought Amylin in 2012 for $7 billion. But then in 2014, BMS decided to abandon the business altogether.
Ten years ago, blood thinners wave vertical dimension (Plavix) for BMS to create most of the revenue (sales were $4.76 billion, the same below), other such as antipsychotic Abilify ($1.66 billion) and hypertension treatment drug Avapro and Avalide ($1.2 billion) are pillars of products. Since then, however, the drugs have lost their luster in the face of generic competition.
At the same time, some new products come into play. At the time, BMS had just launched an immunotherapy drug, Orencia. Today, it's a $2.26 billion product. The leukemia drug Sprycel was also a new product, and last year it generated $1.82 billion in sales for BMS.
The biggest change for BMS, however, is the acquisition of Medarex in 2009, a move into tumor immunity. The deal brought ipilimumab (the melanoma drug Yervoy) and the nivolumab (blockbuster pd-1 drug Opdivo). In 2007, the two companies were partners, ironically, when some of the test data had led analysts at Bear Stearns and BMO capital markets to speculate that Yervoy would not be approved by the FDA.
Eliquis's story is similar. It is an anticoagulant, and BMS shares the drug with Pfizer, which is also a profitable product, with sales of $3.34 billion in 2016.
Figure 2. 2007 VS. 2016 pharmaceutical giant revenue and employee changes
Two "strong unions"
Since Fiercepharma website in 2007 operating income since the sort of pharmaceutical companies, the two obvious changes: first, Pfizer acquired Wyeth (Wyeth) in 2009, since then, the latter is gone from the list. That year, wyeth contributed $22 billion to Pfizer's $48 billion in sales. Although the controversy whether or not the wise action has been outside, it has become a case study in some business school), but Pfizer wyeth brought a very important for its products: the pneumococcal vaccine Prevnar, it is the best-selling product, sales of $5.72 billion in 2016. As for Enbrel, an immunotherapy drug from wyeth, and the antidepressant Effexor, it goes without saying that Effexor is a cash cow for Pfizer before losing patent protection.
Secondly, Merck (Merck and schering-plough (Schering Plough) merged, the latter is an important allergic products doesn producers, its cooperation with MSD developed a cholesterol-lowering drug Vytorin and Zetia, these two products until now to face generic competition. In 2007, schering-plough contributed $13 billion to Merck's $24 billion in revenue. Since then, Merck shed schering-plough some combination of products, including doesn, Coppertone, as well as its sell to Bayer (Bayer) in 2014 the great health (Dr. Scholl's consumer healthcare business brand.
Obviously, each of these income data has a story to tell. Novartis's current data including the alcon (this is novartis in 2010 with a deal to buy action), and by 2014 asset swap operations of glaxosmithkline (GSK) of antitumor drugs. Similarly, GSK now sells novartis vaccines and runs a consumer joint venture with the company. In addition, GSK and Shionogi have established a joint venture with ViiV Healthcare, an anti-hiv product. Abbott, one of the Top 15 companies on the Top 15 list in 2007, was split into AbbVie, among the Top 15 companies in the pharmaceutical industry in 2016.
Pharmaceutical industry continues to write these stories, the future will be more initiative, more lose patent protection products, more new products to market by more experiment data were released, all of which may make 2016 recorded by digital change. Will there be a big change to the Top 15 list in 2027? Let's wait and see.
|
